Louisiana 2020 Regular Session

Louisiana Senate Bill SB362

Introduced
2/28/20  
Refer
2/28/20  

Caption

Provides relative to prescriptions for opioids. (8/1/20)

Impact

The proposed changes to existing laws will significantly impact the management of opioid prescriptions in Louisiana. By removing exceptions for first-time prescriptions under seven days, the law will require all opioid prescriptions to be backed by an examination of the PMP. This is expected to help prescribers make more informed decisions, ultimately aiming to reduce the risk of opioid addiction and misuse among patients. Furthermore, it underscores the commitment of the state to combat the ongoing opioid epidemic and promote drug abuse prevention strategies.

Summary

Senate Bill 362, sponsored by Senator Mizell, aims to enhance the prescription monitoring program (PMP) related to opioid prescriptions in Louisiana. The bill mandates that healthcare practitioners access the PMP before prescribing any opioid, irrespective of whether the supply is for more or less than a seven-day duration. This requirement is designed to improve patient safety and prevent prescription drug abuse by ensuring that prescribers are informed about a patient’s prescription history before issuing opioid medications. The new measures will take effect on August 1, 2020.

Sentiment

The sentiment surrounding SB 362 appears generally supportive among healthcare providers and lawmakers aiming to address opioid misuse. Proponents argue that enhancing the monitoring of prescriptions will provide crucial insights into prescription patterns and help mitigate the risks of over-prescription. However, some concerns may arise regarding the additional administrative burden placed on practitioners, particularly in instances where the PMP may be inaccessible or subject to technical failures. Overall, the sentiment reflects a proactive approach to tackling a pressing public health issue.

Contention

Notable points of contention regarding SB 362 may include discussions around the feasibility and implications of strict compliance with PMP access requirements. Critics may voice concerns about the potential challenges faced by medical practitioners in rural areas, where technology and internet access may be limited. Additionally, discussions will likely arise about balancing regulatory measures with the need for timely patient care, particularly in acute situations where quick access to pain relief is vital. These discussions highlight the ongoing struggle between enhancing oversight and ensuring efficient healthcare delivery.

Companion Bills

No companion bills found.

Similar Bills

CA AB149

Controlled substances: prescriptions.

TX HB2766

Relating to electronic and other controlled substance prescriptions under the Texas Controlled Substances Act; authorizing a fee.

CA AB2789

Health care practitioners: prescriptions: electronic data transmission.

TX HB2174

Relating to controlled substance prescriptions and reimbursement for treatment for certain substance use disorders; authorizing a fee.

TX SB1233

Relating to controlled substance prescriptions under the Texas Controlled Substances Act; authorizing a fee.

TX HB2246

Relating to certain procedures applicable to electronic prescriptions for Schedule II controlled substances.

TX SB594

Relating to the regulation of prescriptions for controlled substances, including certain procedures applicable to electronic prescriptions for Schedule II controlled substances.

CA AB852

Health care practitioners: electronic prescriptions.